title: Anti-human leukocyte antigen antibodies after islet transplantation: what do they really mean?
authors.affiliation: Institut de transplantation et de Recherche en Transplantation (ITERT), Department of Nephrology and Clinical Immunology, Division of Transplantation, Centre Hospitalier et Universitaire de Nantes, France. diego.cantarovich@chu-nantes.fr
authors.forename: Diego
authors.initials: D
authors.lastname: Cantarovich
authors.forename: Fabio
authors.initials: F
authors.lastname: Vistoli
authors.forename: Jean-Denis
authors.initials: JD
authors.lastname: Bignon
mesh_terms: D000906:Antibodies / Q000737:chemistry*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000628:therapy*; D006680:HLA Antigens / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism; D007515:Islets of Langerhans / Q000166:cytology*; D016381:Islets of Langerhans Transplantation / Q000379:methods*
chemical_list: D000906:Antibodies; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D007328:Insulin